Introduction
Sarcomas represent less than 1% of all diagnosed cancers and comprise up to 100 different diagnostic categories. Of these categories gastrointestinal stromal tumours (GISTs) are the most common, with an incidence of approximately 14.5 per million people per year as stated in the Swedish tumour registry, and a range of 10-15 per million per year as stated in a recent systematic reviewed published in 2016.
1,2 The management of metastatic and high-risk surgically resected GISTs is focused on the use of imatinib, a tyrosine kinase inhibitor, which has also revolutionised the management of chronic myeloid leukaemia via the abl pathway. 3 It has been shown that GISTs do not respond to conventional cytotoxic chemotherapy. 1 Parkinson's disease (PD) is a progressive neurodegenerative disease that is characterised by a number of motor and non-motor features due to dopaminergic neuronal loss. 4 Meta-analyses have shown that PD prevalence is increasing worldwide with 1,903 per 100,000 being affected in those over 80 years old. In addition, it has been shown that there is a geographic variation in prevalence. Prevalence is higher in westernised countries, with 1,601 per 100,000 affected in North America, Europe and Australia compared to 646 per 100,000 in Asia. 5 PD has the potential to cause signifi cant impact on a patient's function, and pharmacological management is centred on dopamine modulation. There are three cardinal features of PD: bradykinesia, resting tremor and rigidity. A number of rating scales have been developed to objectify PD severity, of which the Unifi ed Parkinson's Disease Rating Scale (UPDRS) is the most established. 4, 6 A revision of the UPDRS by the Movement Disorder Society (MDS-UPDRS) was published in 2008. 7 The MDS-UPDRS includes four domains: 1, non-motor experiences of daily living; 2, motor experiences of daily living; 3, motor examination; and 4, motor complications. We utilised patients ranked on both scores and focused on the third domain (objective motor neurological examination) that we denote as 'UPDRS 3' with R = right side, A = axial features and L = left side.
When assessing PD medication it can often be diffi cult to make a comparison between patients owing to a number of different types of dopaminergic medication and variations in equivalence. A systematic review by Tomlinson et al. provides a standard formula that produces a levodopa equivalent daily dose (LEDD) expressed in milligrams per day. This allows for comparison of dopaminergic medication across patients and studies. 8 We describe two male patients with a concurrent diagnosis of PD and metastatic GIST managed with imatinib and standard therapy for PD. All available UPDRS scores and LEDDs from both electronic fi les and paper case notes were collated. There is a potential observation that expected deterioration in PD may have been slowed by their concurrent management with imatinib.
Imatinib, a tyrosine kinase inhibitor, is the mainstay of treatment for resected high-risk (adjuvant and metastatic) gastrointestinal stromal tumour (GIST) -a rare form of sarcoma. There has been recent research into the neuroprotective role and modulation of dopaminergic neurones by imatinib through the abl pathway in Parkinson's disease (PD). We describe two patients from a single cancer centre with concurrent diagnoses of PD and metastatic GIST receiving imatinib and standard PD management. The cases highlight a potential reduction in PD progression using Uni ed Parkinson's Disease Rating Scale. Further research into repurposing of imatinib for PD may provide additional management options for this neurodegenerative illness. (bradykinesia = 13; rigidity = 2; tremor = 4; postural instability = 0). Examination showed slightly affected speech, mildly reduced facial expression with reduced blinking, bilaterally slowed fi nger tapping, hand movements, pronation/supination, reduced right-sided toe tapping and arising from chair, reduced right arm swing with stooped posture and bilateral tremor. As of January 2018, dopaminergic therapy equated to LEDD 1,425. Both dopaminergic treatment and complete UPDRS 3 scores are displayed chronologically in Figure 2 . 
Discussion
These two cases raise the possibility that imatinib may modulate the severity of PD. Both patients report their PD symptoms being less troublesome despite receiving additional treatment for their comorbid tumours, which is unusual considering that most PD patients with intercurrent illness report subjective worsening. 9 Some corroboration of this clinical impression comes from the routinely obtained UPDRS 3 scores, which show stability or improvement since the introduction of imatinib.
The pathology of PD is well known. This involves the loss of dopaminergic neurones in the substantia nigra and development of Lewy bodies in multiple other brain regions. 10 It is believed that the majority of cases are caused by interplay of genetic and environmental factors.
Mutations in PRKN gene encoding for Parkin, an ubiquitin E3 ligase involved in the degradation of misfolded proteins and mitochondrial function, is the most common cause of autosomal recessive PD. 11, 12 However, it has recently been shown that Parkin may play a role in sporadic PD as it is inactivated owing to nitrosative stress (as a result of reactive nitrogen species), dopaminergic stress and oxidative stress: key pathophysiological processes in sporadic PD. 12 A study from 2010 showed that tyrosine kinase c-abl phosphorylation of Parkin, which is activated during dopaminergic stress as shown in post-mortem studies, inhibited Parkin's ligase and protective function. Therefore, c-abl inhibition may be a neuroprotective strategy in the management of PD. 13 Imatinib, the drug of choice for highrisk adjuvant (surgically resected) GIST, has activity against a number of kinases, but of importance in this context, abl. 14, 15 It is diffi cult to draw defi nite conclusions from two cases regarding progression, but we can benchmark our observations against an average increase in UPDRS by 1.2 points per year in a large cohort study. 16 These fi ndings are therefore preliminary, but suggest that observational data on a wider scale, including other diagnoses in which this drug class is used, would be worthwhile. Future work could be carried out with inclusion of this cancer centre's chronic myeloid leukaemia/PD cohort to increase sample size and clarify the correlation between UPDRS, LEDD and tyrosine kinase therapy.
There are a number of additional limitations that need to be considered. One is the use of dopaminergic medicines and the frequency at which PD medication is changed. In an attempt to standardise this often diffi cult area, we used LEDD as described above.
The use of UPDRS 3 should objectify patients' symptomatology; however, there is the possibility that external factors may have infl uenced clinical examination. We used the UPDRS 3 score, which relates to specialist neurological examination and not the more subjective UPDRS domains, such as patients' experiences of daily living. One can make the assumption that, in particular, the non-motor experiences of daily living (UPDRS 1), which include cognitive impairment, depressed mood, anxiety and apathy, may be infl uenced by the diagnosis of metastatic cancer. 6 We used all available UPDRS 3 scores from both electronic notes and paper case notes since PD diagnosis. The use of UPDRS has become more widely used in recent years, which allows for more accurate observations compared to those years nearer PD diagnosis.
Clinical trials in the USA are now in the recruiting phase to assess the impact of another tyrosine kinase inhibitor, nilotinib, and it will be interesting to see their results. 17 
Conclusion
Although we did not aim to prove the benefi ts of imatinib on PD progression, it does provide observational data that suggests stability or improvement in PD severity related to imatinib therapy. This is consistent with preclinical observations. Several learning points have been identifi ed:
• Phosphorylation of Parkin has a detrimental effect on neuroprotection in PD.
• There is possible modulation of PD using a tyrosine kinase inhibitor, which may help stabilise patients' symptomatology.
• Identifi cation of pathways in rarer diseases may allow for repurposing of medication across medical specialties.
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